Loading…
Rubicon Research (RUBICON)₹1,772+2.36%Pharmaceuticals
Rubicon Research is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 100.5 against a peer median of 47.0, and ROCE of 27.9% against a peer median of 24.0%, and latest-quarter sales growth of 51.8% against a peer median of 26.0%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 42,108 | 41.5 | 24.0 | 20.0 | 0.31 | 0.2 | 9,187 | 940 | 22.8 | 35.8 | vs RUBICON |
| Ajanta Pharma | 41,800 | 33.1 | 35.0 | 27.0 | 0.06 | 1.8 | 5,442 | 1,055 | 32.4 | 49.3 | vs RUBICON |
| Sai Life Sciences | 38,940 | 107.0 | 20.0 | 15.4 | 0.12 | 0.0 | 2,197 | 349 | 11.6 | 21.6 | vs RUBICON |
| Wockhardt | 32,910 | 81.0 | 8.0 | 6.1 | 0.45 | 0.0 | 3,364 | 199 | 26.0 | — | vs RUBICON |
| Piramal Pharma | 32,767 | — | 3.0 | −3.9 | 0.70 | 0.0 | 8,842 | −327 | 27.9 | — | vs RUBICON |
| Acutaas Chemicals | 31,798 | 72.5 | 32.0 | 24.0 | 0.02 | 0.1 | 1,340 | 356 | 42.7 | 71.0 | vs RUBICON |
| Rubicon Research | 29,334 | 100.5 | 27.9 | 27.0 | 0.24 | 0.1 | 1,758 | 248 | 51.8 | 97.4 | — |
| Neuland Laboratories | 26,012 | 52.5 | 26.0 | 21.2 | 0.16 | 0.2 | 2,017 | 364 | 119.4 | 956.7 | vs RUBICON |
| Alembic Pharmaceuticals | 20,041 | 28.9 | 13.1 | 13.5 | 0.25 | 1.2 | 7,321 | 671 | 25.6 | 11.5 | vs RUBICON |
| Granules India | 19,820 | 29.6 | 16.0 | 13.8 | 0.30 | 0.2 | 5,343 | 593 | 22.3 | 59.3 | vs RUBICON |
| Caplin Point Laboratories | 19,024 | 28.7 | 25.1 | 20.6 | 0.00 | 0.3 | 2,186 | 651 | 19.6 | 18.5 | vs RUBICON |
| Peer median | 31,798 | 47.0 | 24.0 | 20.0 | 0.24 | 0.2 | 3,364 | 364 | 26.0 | 49.3 |
Listed companies closest to Rubicon Research in Pharmaceuticals include Emcure Pharmaceuticals, Ajanta Pharma, Sai Life Sciences, Wockhardt, Piramal Pharma, Acutaas Chemicals, Neuland Laboratories, Alembic Pharmaceuticals.
Emcure Pharmaceuticals, with a market cap of ₹42,108 Cr.
Rubicon Research trades at a P/E of 100.5; the median of its peer set is 47.0. A P/E above or below the median is a description, not a judgement on value.
Rubicon Research's return on capital employed is 27.9%, above the peer median of 24.0%.